Calypso Biotech, a preclinical-stage spin-off from Merck Serono, develops therapeutic antibodies for severe diseases of the gastro-intestinal tract.
Cooperation possibilities
Calypso Biotech is willing to enter into collaboration(s) to support the pharmacological validation of CALY-001 and CALY-002 in translational medicine experiments, develop biomarkers, and support IND-enabling studies, including manufacturing.
